Obicetrapib for use in methods for treating a subject having heterozygous familial hypercholesterolemia (HEFH) and / or atherosclerotic cardiovascular disease (ASCVD)

Obicetrapib effectively lowers LDL-C and reduces MACE events in subjects with HeFH and ASCVD, addressing the limitations of statin therapy by offering a complementary pharmacological approach.

WO2026062050A1 Publication Date: 2026-03-26NEWAMSTERDAM PHARMA BV
9 Cites 0 Cited by

Patent Information

Application Number
PCT/EP2025/076528
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-03-04
Filing Date
2025-09-17
Publication Date
2026-03-26

AI Technical Summary

Technical Problem

Existing treatments with statins fail to achieve acceptable LDL-C levels in two-thirds of patients with atherosclerotic cardiovascular disease (ASCVD) and heterozygous familial hypercholesterolemia (HeFH), necessitating a need for additional pharmacological interventions to lower LDL-C effectively.

Method used

Administration of obicetrapib or its pharmaceutically acceptable salts, hydrates, or solvates to subjects with HeFH and/or ASCVD, either alone or in combination with lipid-modifying therapies, to reduce the risk of major adverse cardiovascular events (MACE) such as coronary heart disease, myocardial infarction, stroke, and coronary revascularization.

Benefits of technology

Obicetrapib significantly reduces LDL-C levels and the risk of MACE events, demonstrating efficacy in subjects who do not respond adequately to statin therapy, thereby providing a therapeutic benefit beyond conventional treatments.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The disclosure provides methods of treating heterozygous familial hypercholesterolemia (HeFH) and / or atherosclerotic cardiovascular disease (ASCVD), more particularly in subjects who require additional lowering of low-density lipoprotein cholesterol (LDL-C). The method comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising obicetrapib or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
Need to check novelty before this filing date? Find Prior Art